P3 Health Partners Confirms Nasdaq Listing for PIII & PIIIW

TL;DR

**P3 Health Partners 8-K confirms Nasdaq listing for common stock and warrants, business as usual.**

AI Summary

P3 Health Partners Inc. filed an 8-K on January 10, 2024, reporting on events from January 9, 2024, primarily concerning its Class A common stock (PIII) and Warrants (PIIIW) listed on The Nasdaq Stock Market LLC. This filing updates investors on the company's current registration status and confirms its listed securities. For investors, this matters because it reaffirms the company's compliance with SEC regulations and its continued listing on a major exchange, providing transparency and liquidity for their holdings.

Why It Matters

This filing confirms P3 Health Partners' continued compliance with SEC regulations and its active listing on The Nasdaq Stock Market, which is crucial for investor confidence and stock liquidity.

Risk Assessment

Risk Level: low — This 8-K filing is largely administrative, confirming existing information about the company's listed securities, and does not introduce new financial risks.

Analyst Insight

A smart investor would note this filing as a routine compliance update, confirming the company's continued listing and operational status, but it doesn't provide new information to drive immediate investment decisions.

Key Numbers

• $0.0001 — Par value per share (for Class A common stock)
• $11.50 — Warrant exercise price (for each whole warrant)

Key Players & Entities

• P3 Health Partners Inc. (company) — the registrant filing the 8-K
• The Nasdaq Stock Market LLC (company) — the exchange where P3 Health Partners' securities are registered
• $0.0001 (dollar_amount) — par value per share of Class A common stock
• $11.50 (dollar_amount) — exercise price for each whole warrant

FAQ

Key Financial Figures

• $0.0001 — stered Class A common stock, par value $0.0001 per share PIII The Nasdaq Stock Market
• $11.50 — A common stock at an exercise price of $11.50 PIIIW The Nasdaq Stock Market LLC Ind

Filing Documents

• piii-20240109.htm (8-K) — 33KB
• piii-20240109xexx991.htm (EX-99.1) — 33KB
• image_0.jpg (GRAPHIC) — 67KB
• piii-20240109_g1.jpg (GRAPHIC) — 201KB
• 0001628280-24-000993.txt ( ) — 803KB
• piii-20240109.xsd (EX-101.SCH) — 2KB
• piii-20240109_def.xml (EX-101.DEF) — 15KB
• piii-20240109_lab.xml (EX-101.LAB) — 30KB
• piii-20240109_pre.xml (EX-101.PRE) — 16KB
• piii-20240109_htm.xml (XML) — 4KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. To the extent information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) relates to a completed fiscal period, such information is incorporated by reference into this Item 2.02.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On January 9, 2024, P3 Health Partners Inc. (the "Company") issued a press release reaffirming the full-year 2023 financial guidance that the Company provided in its November 8, 2023 earnings release. The Company has also provided financial guidance and its projected Medicare Advantage membership for the fiscal year ending December 31, 2024. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The Company previously announced that members of its senior management will participate in the 42nd Annual J.P. Morgan Healthcare Conference (the "JPM Conference") on January 10, 2024. The Company expects to present at the JPM Conference at approximately 1:30 PM PT (4:30 PM ET), and the presentation will be available through a live audio webcast. The presentation materials can be found on the investor relations page of the Company's website (ir.p3hp.org), along with instructions for accessing the webcast (as previously provided through a news wire release on January 2, 2024). The information in Item 2.02 and Item 7.01, including the information contained in Exhibit 99.1 of this Current Report on Form 8-K, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained herein are forward-looking statements. These statements include, but are not limited to, statements about the Company's p

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release of the Company, dated January 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. P3 Health Partners Inc. Date: January 9, 2024 By: /s/ Jessica Puathasnanon Jessica Puathasnanon Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR